Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jaguar HealthJAGX -6.54%21 Receivables Turnover is 25.48 as of Mar. 2026. GuruFocus rates JAGX with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 842 Biotechnology companies, Jaguar Health ranks better than 93.11% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Jaguar Health's Revenue for the
three
months ended in Mar. 2026 was $20.25 Mil. Jaguar Health's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.79 Mil.
Hence, Jaguar Health's Receivables Turnover for the
three
months ended in Mar. 2026 was 25.48.
Jaguar Health (NAS:JAGX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Jaguar Health Receivables Turnover Related Terms
Jaguar Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Jaguar Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JAGX vs TCRT, LABT, CPMV: Receivables Turnover Comparison
For the Biotechnology subindustry, Jaguar Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (JAGX) has a Receivables Turnover of 25.48 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jaguar Health and its competitors. According to the industry distribution chart, Jaguar Health ranks #58 out of 842 companies in the Biotechnology industry, placing it in the top 6.9%.
Is Jaguar Health's Receivables Turnover too high?
Jaguar Health's current Receivables Turnover is 25.48. The Biotechnology industry median Receivables Turnover is 5.30. Jaguar Health's value of 25.48 is 381.2% above this industry median. Based on the distribution chart, Jaguar Health ranks #58 out of 842 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jaguar Health has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Receivables Turnover compare to TCRT and LABT?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #58 out of 842 companies for Receivables Turnover. This places Jaguar Health in the top 7% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.30. Jaguar Health's value of 25.48 is 381.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jaguar Health's current Receivables Turnover of 25.48 is 381.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Jaguar Health and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jaguar Health's current Receivables Turnover is 25.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (JAGX) has a current Receivables Turnover of 25.48. The current Receivables Turnover is 25.48 and 381.2% above the Biotechnology industry median of 5.30. Jaguar Health's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Jaguar Health (JAGX), the current Receivables Turnover is 25.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
21GF Score
Get the complete analysis for JAGX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
